{"id":"W4399393998","doi":"10.1200/jco.2024.42.16_suppl.4505","title":"Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Biomarker; Oncology; Internal medicine; Kidney cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002755946,0.0008546558,0.001326361,0.0003218416,0.0002910555,0.001010712,0.0007254269,0.0008262084,0.003531019],"category_scores_gemma":[0.001722491,0.0003977588,0.001303026,0.0004412271,0.0004846335,0.0007046266,0.0004681051,0.001709795,0.0008825462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001056398,"about_ca_system_score_gemma":0.001513575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006464084,"about_ca_topic_score_gemma":0.002332062,"domain_scores_codex":[0.9991553,0.0004187232,0.00003706416,0.0001777491,0.00010944,0.0001017574],"domain_scores_gemma":[0.9990975,0.0001592462,0.0002492607,0.00008649311,0.00006756737,0.0003399453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8391119,0.0139471,0.0305064,0.0007158133,0.00535006,0.0001380844,0.0001705475,0.003646587,0.05388181,0.0002425063,0.004010435,0.04827866],"study_design_scores_gemma":[0.330385,0.4887808,0.1423949,0.00006536892,0.006747297,0.0006881931,0.0001669669,0.004230123,0.01697922,0.0005696258,0.008908497,0.00008392575],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937187,0.001456595,0.0004280341,0.0002714892,0.00006759828,0.0007663228,0.002180906,0.0000598887,0.001050403],"genre_scores_gemma":[0.9940423,0.0003816787,0.0009838737,0.0003087328,0.00004005155,0.0004723123,0.002860505,0.00001607361,0.0008944375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003531019,"threshold_uncertainty_score":0.014575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2035451389313252,"score_gpt":0.4965729459471428,"score_spread":0.2930278070158175,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}